Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2380-0.0191 (-7.43%)
At close: 12:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2571
Open0.2380
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2380 - 0.2380
52 Week Range0.1530 - 0.4660
Volume1,000
Avg. Volume5,393
Market Cap8.818M
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

    Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissueVANCOUVER, BC / ACCESSWIRE / November 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has shipped DermaPreciseTM Injector prototypes and consumables to an independent laboratory in Ge

  • ACCESSWIRE

    RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

    RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearanceVANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it's clinical advisory team has completed the primary design of the next-phase clinical study of its skin rejuvenation product, RCS-01

  • ACCESSWIRE

    RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

    Trademark registrations kickoff pre-commercial planningVANCOUVER, BC / ACCESSWIRE /October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today the DermaPrecise trademark for its dermal injector product portfolio.

Advertisement
Advertisement